SIM
MYGN icon

SummerHaven Investment Management’s Myriad Genetics MYGN Stock Holding History

SummerHaven Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-36,725
Closed -$1.12M – 268
2021
Q2 		$1.12M Buy
36,725
+1,025
+3% +$29.6K 0.64% 40
2021
Q1 		$1.09M Hold
35,700
– – 0.66% 26
2020
Q4 		$706K Buy
+35,700
New +$576K 0.55% 53

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

SummerHaven Investment Management's MYGN Position: Q3 2021 in Review

SummerHaven Investment Management sold out of Myriad Genetics (MYGN) in Q3 2021, closing a stake of 36,725 shares — an estimated $1.12M sold.

SummerHaven Investment Management first reported a position in MYGN in Q4 2020 and held it in 3 quarters. The position peaked at $1.12M in Q2 2021. 213 funds tracked by Wall St. Rank hold MYGN as of Q3 2021.

  • SummerHaven Investment Management reported no remaining Myriad Genetics position as of Q3 2021 after selling out during the quarter.
  • SummerHaven Investment Management sold 36,725 Myriad Genetics shares in Q3 2021, an estimated $1.12M.
  • SummerHaven Investment Management first reported a position in Myriad Genetics in Q4 2020 and held it in 3 quarters.
  • SummerHaven Investment Management's Myriad Genetics position peaked at $1.12M in Q2 2021.
  • 213 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2021.

Based on SummerHaven Investment Management's 13F filing for Q3 2021, filed 20 Oct 2021.